Our observation that knockdown of FKBP11 increases susceptibility to cell death in the alveolar epithelial cell line A549, raises an important concern when considering FKBP11 inhibition as a therapeutic target in IPF. Here, FKBP11 is linked to idiopathic pulmonary fibrosis.